Special Issue

Genetic Architecture of Dementia

Message from the Guest Editors

Dementia is considered to be a result of complex interactions between environmental factors and genetic changes. This Special Issue entitled "Genetic Architecture of Dementia" will focus on the understanding of mechanisms involved in the development of different types of dementia seen from a genomic perspective using advanced state of the art methods to analyze genetic variability and gene interactions. We aim to collect high-quality original articles, commentary, and review articles that focus on the study of genetic pathogenesis of possible key pathways of disease development. We highly encourage the submission of papers that support the results of their genetic research with confirmatory experiments on cell and/or animal models. Understanding the complex genetic background underlying the development of dementia will make it easier to diagnose the causative disease before the onset of irreversible changes, but it also has the potential to aid the discovery of novel mechanisms for the development of targeted therapy.

Guest Editors

Prof. Dr. Fran Borovečki

Department of Functional Genomics, Center for Translational and Clinical Research, University of Zagreb School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia

Prof. Dr. Tiago Fleming Outeiro

Department of Experimental Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany

Deadline for manuscript submissions

closed (31 October 2023)

Biomedicines

Biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).